DGAT1, diacylglycerol O-acyltransferase 1, 8694

N. diseases: 64; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Here we report the discovery and characterization of a novel selective DGAT1 inhibitor 29 to potentially treat obesity. 29699923 2018
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans. 28498655 2017
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Diacylglycerol acyltransferase-1 (DGAT1), a key enzyme in triglyceride (TG) biogenesis, is highly associated with metabolic abnormalities, such as obesity and type 2 diabetes. 26493024 2016
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE These cases of DGAT1 deficiency extend the molecular and phenotypic spectrum of PLE, suggesting a re-evaluation of the use of DGAT1 inhibitors for metabolic disorders including obesity and diabetes. 26883093 2016
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Dgat1(-/-) mice exhibit a number of beneficial metabolic effects including reduced obesity and improved insulin sensitivity and no known cardiac dysfunction. 25157099 2014
CUI: C0028754
Disease: Obesity
Obesity
0.100 AlteredExpression disease BEFREE Pre-existing maternal obesity and GDM are associated with decreased expression in genes involved in fatty acid uptake and intracellular transport (LPL, FATP2, FATP6, FABPpm and ASCL1), triacylglyceride (TAG) biosynthesis (MGAT1,7 MGAT2 and DGAT1), lipogenesis (FASN) and lipolysis (PNPLA2, HSL and MGLL). 24262292 2014
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Findings from genetically modified mice as well as pharmacological studies suggest that inhibition of DGAT1 is a promising strategy for the treatment of obesity and type 2 diabetes. 21990351 2011
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. 18183944 2008
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE These findings suggest that pharmacological inhibition of DGAT1 may be a feasible therapeutic strategy for human obesity and type 2 diabetes. 15569818 2005
CUI: C0028754
Disease: Obesity
Obesity
0.100 GeneticVariation disease BEFREE We tested whether augmentation of triglyceride synthesis in adipose tissue by transgenic overexpression of the diacylglycerol aclytransferase-1 (Dgat1) gene causes obesity and/or alters insulin sensitivity. 16306352 2005
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Importantly, DGAT1 deficiency protects against insulin resistance and obesity in agouti yellow mice, a model of severe leptin resistance. 11956242 2002